2021 | Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib
| JTO Clinical and Research Reports |
2019 | Chronic Lymphocytic Myocarditis Confirmed by Electrogram-Guided Endomyocardial Biopsy | EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING |
2014 | Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma | LUNG CANCER |
2018 | Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival | LUNG CANCER |
2016 | Clinical course of stage IV invasive mucinous adenocarcinoma of the lung | LUNG CANCER |
2016 | Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
| JOURNAL OF TRANSLATIONAL MEDICINE |
2016 | Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. | LUNG CANCER |
2023 | Clinicopathological Characteristics of NRG1 Fusion-Positive Solid Tumors in Korean Patients
| CANCER RESEARCH AND TREATMENT |
2021 | Club cell-specific role of programmed cell death 5 in pulmonary fibrosis
| NATURE COMMUNICATIONS |
2017 | Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma | ANNALS OF ONCOLOGY |
2020 | Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade | JCI INSIGHT |
2019 | Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in non-small cell lung cancer: impact on survival and acute exacerbation
| BMC PULMONARY MEDICINE |
2020 | Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
2019 | Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
| JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
2017 | Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization
| ONCOTARGET |
2016 | Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.
| BMC CANCER |
2014 | Detailed pathologic evaluation on endomyocardial biopsy provides long-term prognostic information in patients with acute myocarditis | CARDIOVASCULAR PATHOLOGY |
2017 | Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis
| ONCOTARGET |
2012 | Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
| CANCER |
2021 | Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
2010 | Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
2021 | Dynamic changes in circulating PD-1(+)CD8(+)T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
2019 | Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy | LUNG CANCER |
2021 | Dysregulation of T FH-B-T RM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer
| NATURE COMMUNICATIONS |
2022 | Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience | CANCER IMMUNOLOGY IMMUNOTHERAPY |
2013 | EGFR and TTF-1 Gene Amplification in Surgically Resected Lung Adenocarcinomas: Clinicopathologic Significance and Effect on Response to EGFR-Tyrosine Kinase Inhibitors in Recurred Cases | ANNALS OF SURGICAL ONCOLOGY |
2018 | Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. | CANCER RESEARCH |
2021 | Erdheim-Chester disease presenting as an intracardiac mass and pericardial effusion confirmed by biopsy: a case report
| EUROPEAN HEART JOURNAL-CASE REPORTS |
2018 | Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation | LUNG CANCER |
2013 | Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer | JOURNAL OF CLINICAL ONCOLOGY |
2021 | Genetic Analysis and Operative Outcomes in Patients with Oncogene-Driven Advanced NSCLC Treated with Cytoreductive Surgery as a Component of Local Consolidative Therapy
| CANCERS |
2022 | Genomic characteristics of invasive mucinous adenocarcinoma of the lung with multiple pulmonary sites of involvement
| MODERN PATHOLOGY |
2016 | Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative
| ONCOTARGET |
2012 | High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma
| CLINICAL CANCER RESEARCH |
2010 | Histopathologic findings of transbronchial biopsy in usual interstitial pneumonia | PATHOLOGY INTERNATIONAL |
2019 | Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer | Annals of Oncology |
2020 | Identification of Fungal Species and Detection of Azole-Resistance Mutations in the Aspergillus fumigatus cyp51A Gene at a South Korean Hospital
| YONSEI MEDICAL JOURNAL |
2014 | Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
| GENOME MEDICINE |
2003 | Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma | EUROPEAN UROLOGY |
2022 | Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations
| CANCER RESEARCH AND TREATMENT |
2019 | Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma | LUNG CANCER |
2014 | KRAS oncogene substitutions in Korean NSCLC patients: Clinical implication and relationship with pAKT and RalGTPases expression | LUNG CANCER |
2015 | LAMC2 enhances the metastatic potential of lung adenocarcinoma | CELL DEATH AND DIFFERENTIATION |
2022 | Long-term clinical course and progression of lymphangioleiomyomatosis in a single lung transplant referral centre in Korea
| SCIENTIFIC REPORTS |
2019 | Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer | CLINICAL LUNG CANCER |
2020 | Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
| BRITISH JOURNAL OF CANCER |
2014 | Multifocal micronodular pneumocyte hyperplasia mimicking miliary tuberculosis. | AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE |
2019 | Mutant Thr95Ile Transthyretin-Related Cardiac Amyloidosis With Polyneuropathy
| CIRCULATION JOURNAL |
2017 | Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. | JOURNAL OF CLINICAL ONCOLOGY |
2021 | Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma
| SCIENTIFIC REPORTS |
2022 | Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
2014 | Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma | LUNG CANCER |
2020 | Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer
| CLINICAL CANCER RESEARCH |
2013 | Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma | FUTURE ONCOLOGY |
2014 | Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements
| PLOS ONE |
2020 | Surgical removal of solitary cardiac metastasis of hypopharyngeal cancer | EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING |
2019 | Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
| EMBO MOLECULAR MEDICINE |
2013 | TGF-β1 T869C Polymorphism May Affect Susceptibility to Idiopathic Pulmonary Fibrosis and Disease Severity | LUNG |
2023 | The deubiquitinase UCHL3 mediates p300-dependent chemokine signaling in alveolar type II cells to promote pulmonary fibrosis
| EXPERIMENTAL AND MOLECULAR MEDICINE |
2015 | The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer | LUNG CANCER |